Cardiomyopathies Epidemiology Analysis and Forecast, 2021-2031

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

In the 7MM, the diagnosed prevalent cases of cardiomyopathies was 2,268,240 cases in 2021. The market is expected to grow at an AGR of more than 2% during the forecast period. Cardiomyopathy is a general term for a collection of diverse conditions of the heart muscle that inhibit the heart muscle’s ability to pump blood. The main forms of cardiomyopathy are dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy (RCM), and arrhythmogenic right ventricular cardiomyopathy (ARCM), which combined are referred to as cardiomyopathies in this report.

What are the key subtypes in the Cardiomyopathies market?

The key subtypes in the Cardiomyopathies market are DCM, HCM, RCM, and ARCM. In 2021, DCM and HCM were the most common cardiomyopathy subtypes in the 7MM.

Cardiomyopathies market, by subtypes

Cardiomyopathies market, by subtypesFor more subtype insights, download a free report sample

Diagnosed Prevalent Cases of Cardiomyopathies by Etiology

The two segments in the diagnosed prevalent cases of cardiomyopathies by etiology are acquired and familial. The most diagnosed cases of cardiomyopathies in the 7MM were acquired in 2021. This trend is attributed to two factors. The first is largely due to the large number of cases in the US. The second is due to the large number of diagnosed DCM cases in the US, France, Italy, and the UK, where the proportion of acquired cases is higher than in other cardiomyopathy subtypes.

Cardiomyopathies market, by etiology

Cardiomyopathies market, by etiology

For more etiology insights, download a free report sample

Diagnosed Prevalent Cases of Dilated Cardiomyopathy with Ischemia

The two key segments in the diagnosed prevalent cases of cardiomyopathies by ischemia are Ischemic and non-ischemic.  In 2021, most diagnosed DCM cases in the 7MM were non-ischemic. This proportion was similar across most markets, except for Germany, Italy, and Japan.

Cardiomyopathies market, by Ischemia

Cardiomyopathies market, by Ischemia

For more ischemia insights, download a free report sample

Market report overview

Market size 2021 2,268,240 cases
AGR% >2%
Forecast period 2021-2031
Key subtype DCM, HCM, RCM, and ARCM
Key prevalent cases of cardiomyopathies by etiology Acquired and Familial
Key diagnosed prevalent cases of cardiomyopathies by ischemia Ischemic and Non-Ischemic

Scope

  • The cardiomyopathies epidemiology report and model provide an overview of the risk factors, comorbidities, and global and historical trends for cardiomyopathies (DCM, HCM, RCM, and ARCM) in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan).
  • The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of cardiomyopathies segmented by subtype, sex, and age (under 18 years, 18–29 years, and by 10-year age groups for ages 30 years up to 80 years and older) in these markets. The diagnosed prevalent cases are further segmented by causes (acquired versus inherited) and ischemic cases (DCM only).
  • The epidemiology model corresponding to this report provides additional clinically relevant segmentations for the diagnosed prevalent cases of cardiomyopathies including subtype specific etiology
  • The cardiomyopathies epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in cardiomyopathies.
  • The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

The Cardiomyopathies Epidemiology series will allow you to:

  • Develop business strategies by understanding the trends shaping and driving the global cardiomyopathies markets.
  • Quantify patient populations in the global cardiomyopathies markets to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for cardiomyopathies therapeutics in each of the markets covered.
  • Understand magnitude of the population with cardiomyopathies by age, sex, etiology, and ischemia (DCM only).

Table of Contents

| About GlobalData

1 Cardiomyopathies: Executive Summary

1.1 Related Reports

1.2 Upcoming Reports

2 Epidemiology

2.1 Disease Background

2.1.1 Risk Factors and Comorbidities

2.2 Global and Historical Trends

2.3 Forecast Methodology

2.3.1 Sources

2.3.2 Forecast Assumptions and Methods

2.3.3 Diagnosed Prevalent Cases of Dilated Cardiomyopathy

2.3.4 Diagnosed Prevalent Cases of Hypertrophic Cardiomyopathy

2.3.5 Diagnosed Prevalent Cases of Restrictive Cardiomyopathy

2.3.6 Diagnosed Prevalent Cases of Arrhythmogenic Cardiomyopathy

2.3.7 Diagnosed Prevalent Cases of Cardiomyopathies by Etiology

2.3.8 Diagnosed Prevalent Cases of Dilated Cardiomyopathy with Ischemia

2.4 Epidemiological Forecast for Cardiomyopathies (2021–2031)

2.4.1 Diagnosed Prevalent Cases of Cardiomyopathies

2.4.2 Diagnosed Prevalent Cases of Cardiomyopathies by Subtype

2.4.3 Age-Specific Diagnosed Prevalent Cases of Cardiomyopathies

2.4.4 Sex–Specific Diagnosed Prevalent Cases of Cardiomyopathies

2.4.5 Diagnosed Prevalent Cases of Cardiomyopathies by Etiology

2.4.6 Diagnosed Prevalent Cases of Dilated Cardiomyopathy with Ischemia

2.5 Discussion

2.5.1 Epidemiological Forecast Insight

2.5.2 COVID-19 Impact

2.5.3 Limitations of the Analysis

2.5.4 Strengths of the Analysis

3 Appendix

3.1 Bibliography

3.2 Primary Research – Prescriber Survey

3.3 About the Authors

3.3.1 Epidemiologist

3.3.2 Reviewers

3.3.3 Global Director of Therapy Analysis and Epidemiology

3.3.4 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

Table

Table 1: Risk factors and comorbidities for cardiomyopathies

Table 2: High-prescribing physicians (non-KOLs), surveyed by country, 2022

Figures

Figure 1: 7MM, diagnosed prevalent cases of cardiomyopathies, both sexes, all ages, N, 2021 and 2031

Figure 2: 7MM, diagnosed prevalence of cardiomyopathies (%), men and women, all ages, 2021

Figure 3: Sources used and not used for diagnosed prevalent cases of dilated cardiomyopathy

Figure 4: Sources used and not used for diagnosed prevalent cases of hypertrophic cardiomyopathy

Figure 5: Sources used for diagnosed prevalent cases of restrictive cardiomyopathy

Figure 6: Sources used for diagnosed prevalent cases of arrhythmogenic cardiomyopathy

Figure 7: Sources used for diagnosed prevalent cases of dilated cardiomyopathy by etiology

Figure 8: Sources used for diagnosed prevalent cases of hypertrophic cardiomyopathy by etiology

Figure 9: Sources used for diagnosed prevalent cases of restrictive cardiomyopathy by etiology

Figure 10: Sources used for diagnosed prevalent cases of arrhythmogenic cardiomyopathy by etiology

Figure 11: 7MM, diagnosed prevalent cases of cardiomyopathies in 2021, men and women, N, all ages

Figure 12: 7MM, diagnosed prevalent cases of cardiomyopathies by subtype, men and women, all ages, N, 2021

Figure 13: 7MM, age-specific diagnosed prevalent cases of cardiomyopathies, men and women, all ages, N, 2021

Figure 14: 7MM, diagnosed prevalent cases of cardiomyopathies by sex, all ages, N, 2021

Figure 15: 7MM, Diagnosed Prevalent Cases of Cardiomyopathies by Etiology, Men and Women, All Ages, N, 2021

Figure 16: 7MM, diagnosed prevalent cases of ischemic dilated cardiomyopathy, men and women, all ages, N, 2021

Frequently asked questions

Cardiomyopathies Epidemiology Analysis and Forecast, 2021-2031 standard reports
Currency USD
$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Cardiomyopathies Epidemiology Analysis and Forecast, 2021-2031 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Cardiomyopathies Epidemiology Analysis and Forecast, 2021-2031 in real time.

  • Access a live Cardiomyopathies Epidemiology Analysis and Forecast, 2021-2031 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.